Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) has announced its consolidated financial results for the quarter ended June 30, 2025, reporting a strong performance across both domestic and international markets.
The company’s revenue from operations stood at ₹2,101 crore, marking a 15.7% year-on-year (YoY) growth. EBITDA rose by 20.1% YoY to ₹404 crore, with EBITDA margins improving to 19.2%. Profit After Tax (PAT) reached ₹215 crore, reflecting a 41% YoY increase, with PAT margins improving to 10.2% from 8.4% in Q1 FY25.
The domestic business reported sales of ₹995 crore, registering 9.4% growth YoY, driven by strong performance across key therapeutic areas, including dermatology and OTC segments. The company also expanded its strategic partnership with Sanofi during the quarter. As part of this collaboration, Emcure will now market and distribute Sanofi’s Oral Anti-diabetic portfolio, in addition to its cardiovascular range.
The international business achieved ₹1,106 crore in revenue, reflecting 22.1% YoY growth. The Rest of the World markets grew by 41.9%, while the Canada business grew by 16.4%, supported by new product launches and increased market share. The European business posted 12.8% growth, aided by early benefits of recent launches.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said:
“We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins.”
Consolidated Financial Highlights – Q1 FY26:
Revenue from operations: ₹2,101 crore vs ₹1,815 crore in Q1 FY25 (↑15.7% YoY)
EBITDA: ₹404 crore vs ₹336 crore (↑20.1% YoY); EBITDA margin: 19.2%
PAT: ₹215 crore vs ₹153 crore (↑41% YoY); PAT margin: 10.2%
Domestic business: ₹995 crore vs ₹909 crore (↑9.4% YoY)
International business: ₹1,106 crore vs ₹906 crore (↑22.1% YoY)
Rest of the World (EM): ₹360 crore vs ₹254 crore (↑41.9% YoY)
Europe (EU): ₹403 crore vs ₹358 crore (↑12.8% YoY)
Canada (CA): ₹342 crore vs ₹294 crore (↑16.4% YoY)
Emcure continues to focus on strengthening its global footprint and product pipeline through a combination of in-licensing, in-house development, and strategic partnerships. The company operates in over 70 countries and ranks as the 12th largest pharmaceutical company in India by domestic sales (MAT June 2024).
